Schroder Investment Management Group Acquires New Holdings in Tango Therapeutics, Inc. (NASDAQ:TNGX)

Schroder Investment Management Group acquired a new position in Tango Therapeutics, Inc. (NASDAQ:TNGX - Free Report) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund acquired 655,158 shares of the company's stock, valued at approximately $2,031,000. Schroder Investment Management Group owned about 0.61% of Tango Therapeutics at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of the company. American Century Companies Inc. boosted its stake in Tango Therapeutics by 12.4% during the 4th quarter. American Century Companies Inc. now owns 110,448 shares of the company's stock worth $341,000 after purchasing an additional 12,162 shares during the last quarter. Teacher Retirement System of Texas lifted its stake in shares of Tango Therapeutics by 35.8% in the fourth quarter. Teacher Retirement System of Texas now owns 14,544 shares of the company's stock worth $45,000 after buying an additional 3,831 shares in the last quarter. Swiss National Bank boosted its position in Tango Therapeutics by 13.1% during the fourth quarter. Swiss National Bank now owns 94,900 shares of the company's stock worth $293,000 after acquiring an additional 11,000 shares during the last quarter. Sequoia Financial Advisors LLC purchased a new stake in Tango Therapeutics during the 4th quarter valued at about $45,000. Finally, Charles Schwab Investment Management Inc. raised its holdings in Tango Therapeutics by 5.4% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 513,429 shares of the company's stock valued at $1,586,000 after acquiring an additional 26,192 shares during the last quarter. 78.99% of the stock is currently owned by institutional investors and hedge funds.

Tango Therapeutics Stock Up 9.3 %

Shares of Tango Therapeutics stock traded up $0.12 on Friday, hitting $1.41. 352,165 shares of the company were exchanged, compared to its average volume of 1,069,570. The company has a 50-day moving average price of $1.96 and a 200 day moving average price of $3.47. The stock has a market capitalization of $152.43 million, a price-to-earnings ratio of -1.19 and a beta of 1.03. Tango Therapeutics, Inc. has a 1-year low of $1.11 and a 1-year high of $12.02.

Tango Therapeutics (NASDAQ:TNGX - Get Free Report) last released its quarterly earnings data on Thursday, February 27th. The company reported ($0.35) earnings per share for the quarter, missing analysts' consensus estimates of ($0.32) by ($0.03). Tango Therapeutics had a negative return on equity of 49.64% and a negative net margin of 284.42%. The company had revenue of $4.12 million for the quarter, compared to analyst estimates of $7.84 million. Research analysts forecast that Tango Therapeutics, Inc. will post -1.19 EPS for the current year.

Insider Activity

In other news, CEO Barbara Weber sold 9,778 shares of the firm's stock in a transaction that occurred on Tuesday, February 4th. The shares were sold at an average price of $2.99, for a total transaction of $29,236.22. Following the completion of the sale, the chief executive officer now owns 1,631,264 shares in the company, valued at $4,877,479.36. This trade represents a 0.60 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In the last quarter, insiders have sold 24,268 shares of company stock valued at $72,561. 6.30% of the stock is currently owned by insiders.

Tango Therapeutics Profile

Tango Therapeutics, Inc, a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions.